Company
Myoscience
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
3
510(k), De Novo and PMA
Device trials
0
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
Recall records
2
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$123M
9 Form D offerings, 2010 to 2018
Equity
$106M
Stock sold for cash
Debt and convertible notes
$15.6M
$15.6M of it convertible
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: convertible note, $5.0M raised, first sale Oct 30, 2018, 4 investors. $556K was in other or unstated securities.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Oct 30, 2018 | Convertible note | $5.0M | Open-ended | 4 | Rule 506(b) | Form D ↗Nov 13, 2018 |
| Mar 5, 2018 | Equity | $30.9M | $40.9M | 17 | Rule 506(b) | Form D ↗Mar 7, 2018 |
| Mar 7, 2017 | Options or warrants | $556K | $556K | 3 | Rule 506(b) | Form D ↗Mar 21, 2017 |
| Nov 30, 2016 | Equity | $14.0M | $21.0M | 2 | Rule 506(b) | Form D/A ↗Oct 18, 20171 amendment |
| Jul 22, 2014 | Convertible note | $8.4M | $11.5M | 28 | Rule 506(b)Agent: n/a | Form D ↗Sep 26, 2014 |
| Sep 18, 2013 | Equity | $10.0M | $24.8M | 35 | Rule 506(b)Agent: N/A | Form D ↗Oct 9, 2013 |
| Mar 21, 2012 | Equity | $32.7M | $45.0M | 32 | Rule 506Agent: American Equities Overseas, Inc. | Form D ↗Apr 2, 2012 |
| Mar 4, 2011 | Equity | $18.8M | $26.2M | 35 | Rule 506 | Form D ↗Mar 16, 2011 |
| Aug 16, 2010 | Convertible note | $2.2M | $3.0M | 8 | Rule 506 | Form D ↗Aug 30, 2010 |
Company details
From the company's latest Form D.
- Legal name
- MYOSCIENCE, INC
- Headquarters
- Fremont, California
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other
- SEC filer
- CIK 1363104 ↗
Executives, directors and promoters
As listed on the latest Form D.
- Brian FarleyDirector
- Jon SerbousekDirector
- Bernard CoulieDirector
- Jan PansaertDirector
- Anthony LandoDirector
- Sam Mawn-MahlauExecutive Officer, Assistant Corporate Secretary
- Timothy StillExecutive Officer, Director, CEO
- Darnard GuillaumeDirector
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Myoscience.
Latest FDA decisions
- iovera system510(k)
K173763 · Decided Feb 28, 2018 · 79 days after receipt
Device type: Device, Surgical, Cryogenic (GXH) · Neurology & Neurosurgery
- iovera system510(k)
K161835 · Decided Mar 24, 2017 · 262 days after receipt
Device type: Device, Surgical, Cryogenic (GXH) · Neurology & Neurosurgery
- Myoscience iovera system510(k)
K142866 · Decided Jan 21, 2015 · 112 days after receipt
Device type: Device, Surgical, Cryogenic (GXH) · Neurology & Neurosurgery
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
No device trials list this company as lead sponsor.
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2201-2015 · Started Jul 1, 2015 · Posted by FDA Jul 22, 2015
Reason given: The expiration date on the outer box label and the pouch label for the iovera Smart Tip product is incorrect. Instead of indicating the correct expiration or 2015-12. the labels were incorrectly labeled 2016-05.
Cause as FDA categorized it: Incorrect or no expiration date · Device type: Device, Surgical, Cryogenic (GXH)
Z-1781-2013 · Started Jun 21, 2013 · Posted by FDA Jul 20, 2013
Reason given: The outer box label of the product was labeled with a down revision label which did not include the US labeling requirements, specifically the symbol descriptors and also the "Caution: Federal Law (USA) restricts this device to sale by or on the order of a physician." This product was previously labeled for EU...
Cause as FDA categorized it: Labeling mix-ups · Device type: Device, Surgical, Cryogenic (GXH)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.